The chief executive of Oxford BioMedica has left the door open to a possible takeover, saying some private equity groups could be a good match for the cell and gene therapy developer which rejected multiple unsolicited offers from EQT this year.
Frank Mathias, who has led the FTSE 250 company since 2023, told the FT in an interview that although the group declined a final bid from Sweden’s EQT in February for an undisclosed amount, his company would always consider offers that could be beneficial to growth and shareholders.
“In life, you have different profiles of private equity firms,” Mathias said ahead of Oxford BioMedica’s capital markets day in London on Tuesday. “Not all will fit us but I believe there are a few that can fit us because maybe under a private situation we [would] be able to grow quicker, because they would be able to give us more financial means. This is something that is fair to at least be considered.”